Efficacy and Safety of Coenzyme Q10 Supplementation in Neonates, Infants and Children: An Overview.

Antioxidants (Basel)

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Merseyside L3 5UX, UK.

Published: April 2024

AI Article Synopsis

  • This article is the first to review the effectiveness and safety of coenzyme Q10 (CoQ10) supplementation specifically in younger populations, including neonates, infants, and children.
  • It focuses on cases where CoQ10 supplementation is used due to various medical disorders rather than for healthy individuals, as there is no established need for it in otherwise healthy younger subjects.
  • The review covers a range of clinical conditions, such as CoQ10 deficiency, muscular dystrophy, migraines, and other specific health issues in children.

Article Abstract

To date, there have been no review articles specifically relating to the general efficacy and safety of coenzyme Q10 (CoQ10) supplementation in younger subjects. In this article, we therefore reviewed the efficacy and safety of CoQ10 supplementation in neonates (less than 1 month of age), infants (up to 1 year of age) and children (up to 12 years of age). As there is no rationale for the supplementation of CoQ10 in normal younger subjects (as there is in otherwise healthy older subjects), all of the articles in the medical literature reviewed in the present article therefore refer to the supplementation of CoQ10 in younger subjects with a variety of clinical disorders; these include primary CoQ10 deficiency, acyl CoA dehydrogenase deficiency, Duchenne muscular dystrophy, migraine, Down syndrome, ADHD, idiopathic cardiomyopathy and Friedreich's ataxia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11117623PMC
http://dx.doi.org/10.3390/antiox13050530DOI Listing

Publication Analysis

Top Keywords

efficacy safety
12
younger subjects
12
safety coenzyme
8
coenzyme q10
8
supplementation neonates
8
coq10 supplementation
8
supplementation coq10
8
supplementation
5
coq10
5
q10 supplementation
4

Similar Publications

Dust emissions from open-pit mining pose a significant threat to environmental safety and human health. Currently, the range of dust suppressants used in coal mining is limited, often failing to account for their suitability across various stockpiles. This oversight results in poor infiltration after application, leading to insufficient crust formation and reduced durability.

View Article and Find Full Text PDF

Importance: Trials have not demonstrated superiority of alteplase or tenecteplase vs standard care in patients with mild stroke and have raised safety concerns. Prourokinase is an alternative fibrinolytic that may have a favorable safety profile, and the benefit-risk profile of prourokinase in mild stroke is unknown.

Objective: To investigate the efficacy and safety of prourokinase in mild ischemic stroke within 4.

View Article and Find Full Text PDF

Epilepsy is a common neurological disease that is treated with medications; however, patients with drug-resistant epilepsy, commonly intractable temporal lobe epilepsy, tend to have better control with surgical treatment. While the mainstay of surgical treatment is anterior temporal lobectomy, it carries risk of potential adverse effects hence minimally invasive techniques are now being used as an alternative to open surgery. This systematic review and meta-analysis compare the efficacy and safety of three of the most used techniques: laser interstitial thermal therapy (LITT), radiofrequency ablation (RFA) and stereotactic radiosurgery (SRS).

View Article and Find Full Text PDF

Chordoma is a rare malignant tumor with a higher incidence in males than in females. There is an increasing number of clinical studies related to tyrosine kinase inhibitors (TKIs), yet the efficacy and safety of different drugs vary. In this single-arm meta-analysis evaluating the efficacy and safety of TKIs for chordoma treatment, 12 studies involving 365 patients were analyzed.

View Article and Find Full Text PDF

Purpose: This phase II study is designed to evaluate the combination therapy involving suvemcitug and envafolimab with FOLFIRI in microsatellite-stable or mismatch repair-proficient (MSS/pMMR) colorectal cancer (CRC) in the second-line treatment setting.

Methods: This study is a non-randomized, open-label prospective study comprising multiple cohorts (NCT05148195). Here, we only report the data from the CRC cohort.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!